125 related articles for article (PubMed ID: 1699310)
1. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids.
Ferran C; Dy M; Merite S; Sheehan K; Schreiber R; Leboulenger F; Landais P; Bluestone J; Bach JF; Chatenoud L
Transplantation; 1990 Oct; 50(4):642-8. PubMed ID: 1699310
[TBL] [Abstract][Full Text] [Related]
2. Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release.
Ferran C; Dy M; Sheehan K; Merite S; Schreiber R; Landais P; Grau G; Bluestone J; Bach JF; Chatenoud L
Clin Exp Immunol; 1991 Dec; 86(3):537-43. PubMed ID: 1721015
[TBL] [Abstract][Full Text] [Related]
3. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway.
Ferran C; Dy M; Sheehan K; Schreiber R; Grau G; Bluestone J; Bach JF; Chatenoud L
Eur J Immunol; 1991 Oct; 21(10):2349-53. PubMed ID: 1833202
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation.
Ferran C; Sheehan K; Dy M; Schreiber R; Merite S; Landais P; Noel LH; Grau G; Bluestone J; Bach JF
Eur J Immunol; 1990 Mar; 20(3):509-15. PubMed ID: 2138557
[TBL] [Abstract][Full Text] [Related]
5. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome.
Alegre ML; Gastaldello K; Abramowicz D; Kinnaert P; Vereerstraeten P; De Pauw L; Vandenabeele P; Moser M; Leo O; Goldman M
Transplantation; 1991 Oct; 52(4):674-9. PubMed ID: 1833865
[TBL] [Abstract][Full Text] [Related]
6. Administration of anti-CD3 monoclonal antibody during experimental Chagas' disease induces CD8+ cell-dependent lethal shock.
Jacobs F; Dubois C; Carlier Y; Goldman M
Clin Exp Immunol; 1996 Feb; 103(2):233-8. PubMed ID: 8565305
[TBL] [Abstract][Full Text] [Related]
7. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone.
Alegre ML; Vandenabeele P; Depierreux M; Florquin S; Deschodt-Lanckman M; Flamand V; Moser M; Leo O; Urbain J; Fiers W
J Immunol; 1991 Feb; 146(4):1184-91. PubMed ID: 1825107
[TBL] [Abstract][Full Text] [Related]
8. The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.
Chatenoud L; Ferran C; Bach JF
Curr Top Microbiol Immunol; 1991; 174():121-34. PubMed ID: 1839376
[No Abstract] [Full Text] [Related]
9. Anti-CD3 antibody-induced activated killer cells: cytokines as the additional signals for activation of killer cells in effector phase to mediate slow lysis.
Ting CC; Hargrove ME
Cell Immunol; 1991 Jul; 135(2):273-84. PubMed ID: 1828008
[TBL] [Abstract][Full Text] [Related]
10. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor.
Alegre M; Vandenabeele P; Flamand V; Moser M; Leo O; Abramowicz D; Urbain J; Fiers W; Goldman M
Eur J Immunol; 1990 Mar; 20(3):707-10. PubMed ID: 2138564
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects.
Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
Transplantation; 1993 Apr; 55(4):901-8. PubMed ID: 8097344
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the release of cytokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10.
Donckier V; Flament V; Gérard C; Abramowicz D; Vandenabeele P; Wissing M; Delvaux A; Fiers W; Leo O; Velu T
Transplantation; 1994 May; 57(10):1436-9. PubMed ID: 8197603
[TBL] [Abstract][Full Text] [Related]
13. High-frequency activation of single CD4+ and CD8+ T cells to proliferate and secrete cytokines using anti-receptor antibodies and IL-2(1).
Maraskovsky E; Pech MH; Kelso A
Int Immunol; 1991 Mar; 3(3):255-64. PubMed ID: 1675587
[TBL] [Abstract][Full Text] [Related]
14. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.
Chatenoud L; Ferran C; Legendre C; Thouard I; Merite S; Reuter A; Gevaert Y; Kreis H; Franchimont P; Bach JF
Transplantation; 1990 Apr; 49(4):697-702. PubMed ID: 2109379
[TBL] [Abstract][Full Text] [Related]
15. The role of antibody isotype in IFN-gamma and IL-2 production during anti-CD3-induced T cell proliferation.
Frenken LA; Koene RA; Tax WJ
Transplantation; 1991 Apr; 51(4):881-7. PubMed ID: 1826571
[TBL] [Abstract][Full Text] [Related]
16. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production.
Chavin KD; Qin L; Lin J; Woodward JE; Baliga P; Bromberg JS
Ann Surg; 1993 Oct; 218(4):492-501; discussion 501-3. PubMed ID: 8215640
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of interleukin-2 and interferon-gamma and maintenance of interleukin-4 and interleukin-10 production after administration of an anti-CD3 monoclonal antibody in mice.
Wissing KM; Desalle F; Abramowicz D; Willems F; Leo O; Goldman M; Alegre ML
Transplantation; 1999 Sep; 68(5):677-84. PubMed ID: 10507488
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD3 immunotoxin prevents low-dose STZ/interferon-induced autoimmune diabetes in mouse.
Vallera DA; Carroll SF; Brief S; Blazar BR
Diabetes; 1992 Apr; 41(4):457-64. PubMed ID: 1376702
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.
Ferran C; Dautry F; Mérite S; Sheehan K; Schreiber R; Grau G; Bach JF; Chatenoud L
J Clin Invest; 1994 May; 93(5):2189-96. PubMed ID: 8182150
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD3 antibody-treated mice: in vivo induction of cytolytic activity and TNF production by lung leukocytes.
Stanková J
Int J Cancer; 1992 May; 51(2):259-65. PubMed ID: 1533202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
